5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
![5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one Structure](CAS2/GIF/334826-98-1.gif)
- CAS No.
- 334826-98-1
- Chemical Name:
- 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
- Synonyms
- Gisadenafil;UK 369003;Gisadenafil, 10 mM in DMSO;Gisadenafil,Inhibitor,UK 369003,inhibit,Phosphodiesterase (PDE),UK369003;5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4H-pyrazolo[4,3-d]pyrimidin-7-one;5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyri;5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-;5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one ISO 9001：2015 REACH
- CBNumber:
- CB22485089
- Molecular Formula:
- C23H33N7O5S
- Molecular Weight:
- 519.62
- MDL Number:
- MFCD16619298
- MOL File:
- 334826-98-1.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Gisadenafil | AA00CN79 | 1mg | $176 |
| Gisadenafil | AA00CN79 | 5mg | $370 |
| Gisadenafil | AA00CN79 | 10mg | $537 |
| Gisadenafil | AA00CN79 | 25mg | $810 |
| Gisadenafil 97.00% | Y226671 | 5MG | $520 |
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one Properties
| Boiling point | 701.3±70.0 °C(Predicted) |
|---|---|
| Density | 1.41 |
| pka | 6.91±0.10(Predicted) |
| FDA UNII | S6G4R7DI1C |
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| aablocks | AA00CN79 | Gisadenafil | 334826-98-1 | 1mg | $176 | 2026-05-28 | Buy |
| aablocks | AA00CN79 | Gisadenafil | 334826-98-1 | 5mg | $370 | 2026-05-28 | Buy |
| aablocks | AA00CN79 | Gisadenafil | 334826-98-1 | 10mg | $537 | 2026-05-28 | Buy |
| aablocks | AA00CN79 | Gisadenafil | 334826-98-1 | 25mg | $810 | 2026-05-28 | Buy |
| ACHEMBLOCK | Y226671 | Gisadenafil 97.00% | 334826-98-1 | 5MG | $520 | 2026-05-27 | Buy |
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one Chemical Properties,Uses,Production
Uses
Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP)[1].
in vivo
Gisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels[1].
| Animal Model: | Male Tat-transgenic (Tat-tg) mice (8 weeks old) exposed to hypercapnia[1] |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection; for 2 hours |
| Result: | Largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Also restored the dilation of small (<25 μm) arterioles following hypercapnia. |
IC 50
PDE5A: 3.6 nM (IC50); PDE1A: 9.1 μM (IC50)
References
[1] Silva J, et al. Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. J Neuroinflammation. 2012 Nov 20;9:253. DOI:10.1186/1742-2094-9-253
[2] Rawson DJ, et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem. 2012 Jan 1;20(1):498-509. DOI:10.1016/j.bmc.2011.10.022
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one Preparation Products And Raw materials
Raw materials
Preparation Products
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19936 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49979 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-029-89586680 +86-18192503167 | 1026@dideu.com | China | 9996 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418684 +8618949823763 | sales@tnjchem.com | China | 25356 | 58 |
| DAYANG CHEM (HANGZHOU) CO.,LTD | +86-88938639 +86-17705817739 | info@dycnchem.com | China | 53803 | 58 |
| BOC Sciences | -- | info@bocsci.com | USA | 0 | 65 |
| Guangzhou Younan Technology Co., Ltd | 020-82000279 18988941452 | YN_research@163.com | China | 2928 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24955 | 58 |
| Suzhou Meishi Biotechnology Co., Ltd. | 1173954148q | meishipharma@126.com | China | 20033 | 58 |
View Lastest Price from 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-06-02 | Gisadenafil
334826-98-1
|
$195.00-646.00 | 99.50% | 10g | TargetMol Chemicals Inc. | ||
 |
2025-06-25 | Gisadenafil
334826-98-1
|
$1.10 | 1g | 99.0% min | 100 tons min | Shaanxi Dideu Medichem Co. Ltd |
-
- Gisadenafil
334826-98-1
- $195.00-646.00
- 99.50%
- TargetMol Chemicals Inc.
-
- Gisadenafil
334826-98-1
- $1.10
- 99.0% min
- Shaanxi Dideu Medichem Co. Ltd
